Detalles de la búsqueda
1.
Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma.
Future Oncol
; 19(22): 1535-1547, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37578377
2.
Patient preferences for treatment in relapsed/refractory diffuse large B-cell lymphoma: a discrete choice experiment.
Future Oncol
; 18(25): 2791-2804, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35837970
3.
Burden of illness and outcomes in second-line large B-cell lymphoma treatment: real-world analysis of Medicare beneficiaries.
Future Oncol
; 17(35): 4837-4847, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34645318
4.
Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
Clin Ther
; 46(1): 3-11, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37981560
5.
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Adv Ther
; 41(5): 1938-1952, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494543
6.
Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Expert Rev Pharmacoecon Outcomes Res
; 23(7): 773-787, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37278284
7.
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
Clin Cancer Res
; 29(10): 1894-1905, 2023 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36999993
8.
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
Leuk Lymphoma
; 63(13): 3052-3062, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36048026
Resultados
1 -
8
de 8
1
Próxima >
>>